HOOK News and Press, HOOKIPA Pharma Inc. From 09/15/21

Clinical collaboration to assess HB-200 in combination with KEYTRUDA ® (pembrolizumab) as first-line treatment HOOKIPA poised to advance clinical development program with randomized Phase 2 study in 2022 NEW YORK and VIENNA, Austria, Sept. 15...

NEW YORK and VIENNA, Austria, Sept. 07, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will parti...

Phase 1 HB-200 data recognized at premier oncology meetings, highlighting potential of novel arenaviral platform to deliver a new class of immunotherapeutics HOOKIPA on track to report comprehensive data from oncology and infectious disease programs in the second half of 2021 ...

HOOKIPA’s arenaviral platform technology demonstrated ability to modulate the tumor microenvironment and induce potent melanoma-specific T cell responses A single, intra-tumoral injection of the arenaviral immunotherapeutic resulted in tumor regression in all mice and tumor...

NEW YORK and VIENNA, Austria, Aug. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release second quarter 2021 financia...

Shares of HOOKIPA Pharma Inc. (NASDAQ:HOOK) traded today at $7.35, breaking its 52-week low. This new low was reached on approximately average trading volume as 481,000 shares traded hands, while the average 30-day volume is approximately 418,000 shares. HOOKIPA Pharma Inc is a clinical ...

Shares of HOOKIPA Pharma Inc. (NASDAQ:HOOK) traded today at $7.44, breaking its 52-week low. So far today approximately 481,000 shares have been exchanged, as compared to an average 30-day volume of 445,000 shares. HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developi...

Shares of HOOKIPA Pharma Inc. (NASDAQ:HOOK) traded today at $7.60, breaking its 52-week low. Approximately 481,000 shares have changed hands today, as compared to an average 30-day volume of 655,000 shares. HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a cla...

Shares of HOOKIPA Pharma Inc. (NASDAQ:HOOK) traded today at $8.02, breaking its 52-week low. So far today approximately 481,000 shares have been exchanged, as compared to an average 30-day volume of 643,000 shares. In the past 52 weeks, HOOKIPA Pharma Inc. share prices are bracketed by a...

The following slide deck was published by HOOKIPA Pharma Inc. in conjunction with this event. For further details see: HOOKIPA Pharma (HOOK) Investor Presentation -Sildeshow